News
Multiomics blood test outperforms other tests for colorectal cancer screening
SAN FRANCISCO – A multiomics test detected stage I and II colorectal cancer with 94% sensitivity and specificity, outperforming a fecal...
News
Avelumab maintenance in gastric cancer is down but maybe not out
SAN FRANCISCO – A trial pitting avelumab maintenance against continued chemotherapy was negative, but a flipping of the survival curves during...
News
Dual immunotherapy goes the distance in MSI-H colorectal cancer
SAN FRANCISCO – At a median follow-up of almost 20 months, combination nivolumab and ipilimumab remained highly active as first-line therapy for...
News
Resecting primary tumors fails to boost survival in metastatic CRC
SAN FRANCISCO – In the first randomized trial to report on this practice, median overall survival was about 2 years regardless of whether or not...
News
Cisplatin-gemcitabine is highly active in BRCA/PALB2+ pancreatic cancer
SAN FRANCISCO – About two-thirds of patients had a response with combination cisplatin and gemcitabine, and adding the PARP inhibitor veliparib...
News
Sociodemographic disadvantage confers poorer survival in young adults with CRC
SAN FRANCISCO – Patients with colorectal cancer aged 40 years or younger who lived in areas having low income and low educational attainment, or...
News
Blood test may advance diagnosis of GI cancers
The Circulating Cell-free Genome Atlas (CCGA) study finds that a multicancer assay using targeted methylation sequencing of plasma cell-free DNA...
News
Dual HER2 therapy added to CRT for esophageal cancer is tolerable, active
Addition of both trastuzumab and pertuzumab to neoadjuvant chemoradiotherapy for resectable HER2-positive esophageal adenocarcinoma is feasible...
News
Urothelial cancer: Less gained from immunotherapy in patients with poor performance scores
Among patients given immune checkpoint inhibitors in the first-line setting, overall survival was more than twice as long for those with a good...
News
Standard-dose RT with concurrent chemo found superior for unresectable NSCLC
An update of the RTOG 0617 trial, now at a median follow-up of 5.1 years, finds that overall survival is better with standard-dose RT versus high-...
News
Fertility-sparing surgery is safe for most with epithelial ovarian cancer
Except among women with advanced serous tumors, surgery preserving the unaffected ovary and uterus was not associated with a significantly...
News
Sequential CRT, immunotherapy nets high PFS in node-positive cervical cancer
More than four in five patients were alive and free of disease progression a year after receiving chemoradiotherapy followed by ipilimumab, and...
News
Rituximab maintenance has a durable benefit in follicular lymphoma
At a median of 9 years of follow-up, progression-free survival was extended versus observation but there was no difference in overall survival.
News
Gene signature may help guide initial CLL treatment choice
A 17-gene expression signature may help predict which patients with IGHV-unmutated disease will benefit from frontline FCR chemoimmunotherapy or...
News
Use and costs of CRC end-of-life care differ sharply between U.S., Canada
On average, mean total costs of health care resources in the last month of life were 25% higher for SEER-Medicare patients compared with Ontario...